

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
27 March 2025 (27.03.2025)



(10) International Publication Number  
**WO 2025/062425 A1**

(51) International Patent Classification:

*A61K 31/4166* (2006.01) *A61K 47/10* (2017.01)  
*C07D 233/86* (2006.01) *A61K 47/30* (2006.01)  
*A61K 47/06* (2006.01)

(21) International Application Number:

PCT/IN2024/051781

(22) International Filing Date:

18 September 2024 (18.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202321062597 18 September 2023 (18.09.2023) IN

(71) Applicant: **BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED** [IN/IN]; 407-408, SHARDA CHAMBERS, NEW MARINE LINES, MUMBAI, MAHARASHTRA, INDIA., MUMBAI 400020 (IN).

(72) Inventors: **SHAH, Dharmesh Mahendrabhai**; BDR PHARMACEUTICAL INTERNATIONAL PVT. LTD., "ENGINEERING CENTRE", 6TH FLOOR, 9, MATHEW ROAD, OPERA HOUSE, MUMBAI, MAHARASHTRA, MUMBAI 400004 (IN). **BADIGER, Aravind Manappa**; BDR RESEARCH CENTRE, BDR PHARMACEUTICALS INTERNATIONAL PVT. LTD., SURVEY NO. 51/1,51/1/2,51/2,52/2/1,52/2,54/2; AT: VANSETI VILLAGE, PO: TAJPURA, TALUKA: HALOL, DISTRICT: PANCHMAHALS, GUJARAT 389350 (IN). **UPADHYE, Abhijeet Ashokrao**; BDR RESEARCH CENTRE, BDR PHARMACEUTICALS INTERNATIONAL PVT. LTD., SURVEY NO. 51/1,51/1/2,51/2,52/2/1,52/2,54/2; AT: VANSETI VILLAGE, PO: TAJPURA, TALUKA: HALOL, DISTRICT: PANCHMAHALS, GUJARAT 389350 (IN). **PANCHAL, Samir Babulal**; BDR RESEARCH CENTRE, BDR PHARMACEUTICALS INTERNATIONAL PVT. LTD., SURVEY NO. 51/1,51/1/2,51/2,52/2/1,52/2,54/2; AT: VANSETI VILLAGE, PO: TAJPURA, TALUKA: HALOL, DISTRICT: PANCHMAHALS, GUJARAT 389350 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: AN ORAL SOLID PHARMACEUTICAL FORMULATION OF ENZALUTAMIDE

(57) Abstract: The present invention relates to novel oral solid pharmaceutical formulation of enzalutamide or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient. An enzalutamide pharmaceutical formulation comprising a one or more pharmaceutically acceptable polymers is provided by the present invention. In addition, the present invention also provides an improved process for preparation of enzalutamide oral solid pharmaceutical formulation.

WO 2025/062425 A1